BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

NUHS, Singtel and Ericsson Expand Partnership to Advance AI-Enabled Healthcare and 6G Research

Extended collaboration will accelerate research and development in advanced connectivity and emerging 5G Advanced & future 6G tec...

November 05, 2026 | News

Zuellig Pharma Acquires Hangzhou Facility to Strengthen Clinical Trial Supply in China

The acquisition of our newly licensed Hangzhou facility establishes robust local sourcing capabilities to accelerate and support clinical trials across Chi...

November 05, 2026 | News

Minghui Signs Japan Licensing Deal With ASKA Worth Up to $440 Million for Thyroid Eye Disease Therapy

Minghui Pharmaceutical ("Minghui") and ASKA Pharmaceutical Co., Ltd. ("ASKA") announced that they have entered into an exclusive license agreement fo...

November 05, 2026 | News

APAC Antibody-Drug Conjugates Past Phase 2, and Who Owns Them Now

Seventeen of them have already been licensed outside their home market, and the companies that will sell most of them in the US and Europe are Merck, Astra...

November 05, 2026 | Analysis

Brise Pharmaceuticals and AbbVie Advance Migraine Drug Collaboration Worth Up to $757 Million

Brise Pharmaceuticals Co., Ltd. provided an update on its exclusive license agreement with AbbVie (NYSE: ABBV), which the companies entered in 2024. Under ...

November 04, 2026 | News

Neurophet Partners with RapidAI to Accelerate AI-Powered Alzheimer’s Imaging Solutions in the US

Neurophet, an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced a partnership with RapidAI, a global lea...

November 04, 2026 | News

Farrer Park Hospital Introduces MP1000 Surgical Robot to Expand Access to Minimally Invasive Surgery

Farrer Park Hospital (FPH) announced the introduction of the Edge® Multi-Port Endoscopic Surgical Robot (MP1000) in Singapore. As FPH celebrates its 10...

November 04, 2026 | News

Pierre Fabre Launches BRAFTOVI–MEKTOVI Combination for BRAF-Mutant Lung Cancer in Singapore

New targeted treatment option now available in for adult patients with BRAFV600E mutant advanced non-small cell lung cancer (NSCLC) Launch follows Europ...

November 04, 2026 | News

InventisBio’s Nomelcitinib Achieves Over 70% PASI 90 Response in Phase III Psoriasis Trial

InventisBio Co., Ltd. announced that its JH2 selective TYK2 inhibitor nomelcitinib (D-2570) has met both the primary endpoint and the key s...

November 04, 2026 | News

Zhimeng Biopharma Completes Enrolment of 255 Patients in Pivotal ALS Phase II/III Trial in China

Shanghai Zhimeng Biopharma, Inc. ( "Zhimeng Biopharma") announced that its independently developed next-generation potassium channel opener, CB03-154,...

November 03, 2026 | News

Nuance Pharma Doses First Patient in China Phase III Trial of Actair for House Dust Mite Allergy

Nuance Pharma announced that the first patient has been dosed in the REACH Phase III clinical trial evaluating STG320 (Actair®) for the treatment of ho...

November 03, 2026 | News

APAC-Originated Obesity Drugs in the Clinic, Beyond Semaglutide

Obesity was the most searched therapeutic area of 2026, and for most readers the story still has two names in it. Semaglutide and tirzepatide set the bench...

November 02, 2026 | Analysis

Pretzel Therapeutics Secures UK Approval to Advance PX578 into Phase II Trial for Rare Mitochondrial Disease

Regulatory milestone follows U.S. FDA clearance of Investigational New Drug application in August 2026 Initiation of Phase 2 Trial in POLG-PMD (POLG Dis...

November 02, 2026 | News

Parse Biosciences and Nomic Bio Launch 100-Million-Cell Immune Dataset to Advance AI Drug Discovery

Parse Biosciences, a leading provider of scalable and publicly available single-cell sequencing technology, a subsidiary of QIAGEN, andNomic Bio, a leader ...

November 02, 2026 | News

Stay Connected